Compound tracker
MDMA.
A source-backed research page for trial rows and update notes connected to this compound or investigational product. The page is generated from the Notion tracker and should be read as a living research map, not a medical conclusion.
Claim boundary
Trial registration, company topline, CNPV/rolling-review status, recruitment status, public-dashboard data, or review literature do not equal approval, label, reimbursement, access, safety, or efficacy. Related update rows are shown only when they include visible Last checked text and an explicit Claim boundary.
N/A / Phase 1 / Phase 2 / Phase 3
Phases tracked
Active / Completed / Recruiting
Statuses seen
Trial rows
NCT06905652 Phase 1 Completed updated May 15, 2026
- Condition
- Healthy volunteers
- Sponsor / institution
- University Hospital, Basel, Switzerland
- Start date
- Jul 29, 2025
Tracker note / source boundary
Last checked 2026-05-15 UTC. Claim boundary: registry/basic-science pharmacology tracker only; healthy-volunteer completion does not establish PTSD efficacy, approval, label, reimbursement, access, or broad safety. Registry: completed Phase 1 randomized triple-masked placebo-controlled 3-period crossover; actual n=26; 300mg R-MDMA vs 100mg S-MDMA vs placebo; primary outcome subjective drug effects on visual analogue scales across study days; completion date 2026-05-12.
NCT07584720 Phase 1 Recruiting updated May 13, 2026
- Condition
- Healthy Volunteers
- Sponsor / institution
- Resilient Pharmaceuticals
- Start date
- Apr 23, 2026
Tracker note / source boundary
ClinicalTrials.gov v2 verification on 2026-05-14 | Overall status: RECRUITING | Enrollment: estimated n=32 | Lead sponsor: Resilient Pharmaceuticals | Collaborator: Dr. Vince Clinical Research | Intervention: Midomafetamine HCl | Tracker posture: Phase 1 healthy-volunteer PK/PD/ECG/cardiac-safety characterization; not PTSD efficacy/access.
NCT04030169 Phase 2 Completed updated Jan 28, 2025
- Condition
- PTSD
- Sponsor / institution
- MAPS Europe B.V.
- Start date
- Jun 24, 2020
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 2 | Lead sponsor: MAPS Europe B.V. | Conditions: PTSD
NCT06044675 Phase 2 Recruiting updated Nov 26, 2024
- Condition
- Post Traumatic Stress Disorder
- Sponsor / institution
- Remedy
- Start date
- Nov 15, 2024
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: RECRUITING | Exact phase: Phase 2 | Lead sponsor: Remedy | Conditions: Post Traumatic Stress Disorder
NCT04438512 N/A Stopped updated Nov 5, 2024
- Condition
- Post Traumatic Stress Disorder
- Sponsor / institution
- Lykos Therapeutics
- Start date
- —
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: NO_LONGER_AVAILABLE | Exact phase: Not listed | Lead sponsor: Lykos Therapeutics | Conditions: Post Traumatic Stress Disorder
NCT05948683 Phase 1 Completed updated Aug 19, 2024
- Condition
- MDMA ('Ecstasy'), Social Interaction
- Sponsor / institution
- University of Chicago
- Start date
- Jul 21, 2023
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Early Phase 1 | Lead sponsor: University of Chicago | Conditions: MDMA ('Ecstasy'); Social Interaction
NCT03790618 Phase 1 Completed updated Jan 5, 2024
- Condition
- Healthy, MDMA ('Ecstasy')
- Sponsor / institution
- University of Chicago
- Start date
- Jun 1, 2016
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: University of Chicago | Conditions: Healthy; MDMA ('Ecstasy')
NCT06189027 Phase 3 Active updated Jan 3, 2024
- Condition
- PTSD
- Sponsor / institution
- University of Southern California
- Start date
- Nov 20, 2018
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: UNKNOWN | Exact phase: Phase 3 | Lead sponsor: University of Southern California | Conditions: PTSD
NCT04516902 Phase 1 Completed updated Aug 23, 2022
- Condition
- Healthy
- Sponsor / institution
- University Hospital, Basel, Switzerland
- Start date
- Jan 1, 2021
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Healthy
NCT01270672 N/A Completed updated Dec 11, 2018
- Condition
- Mood Disorder, Substance-Related Disorders, Amphetamine-Related Disorders
- Sponsor / institution
- University Hospital, Basel, Switzerland
- Start date
- —
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Not applicable | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Mood Disorder; Substance-Related Disorders; Amphetamine-Related Disorders
NCT00252174 Phase 2 Stopped updated Nov 14, 2017
- Condition
- Anxiety Disorder, Cancer
- Sponsor / institution
- Brigham and Women's Hospital
- Start date
- —
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: TERMINATED | Exact phase: Phase 2 | Lead sponsor: Brigham and Women's Hospital | Conditions: Anxiety Disorder; Cancer
NCT01447472 Phase 1 Completed updated Oct 6, 2011
- Condition
- Metabolism, Interaction
- Sponsor / institution
- Parc de Salut Mar
- Start date
- —
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: Parc de Salut Mar | Conditions: Metabolism; Interaction
Related updates
May 15, 2026 Last checked 2026-05-15 UTC Publication Research
Claim boundary.qualitative implementation/guideline-context evidence only; not an efficacy trial, not a broad safety finding, and not evidence of approval/access outside the Australian authorized-prescribing context described by the article.
PubMed PMID 41633448 / Journal of Affective Disorders reports a framework-guided qualitative analysis of 21 interviews with Australian clinicians, researchers, and patients after Australia rescheduled MDMA to permit authorized prescribing for PTSD outside clinical trials; intended to inform guideline development.
Source/tracker note
Last checked 2026-05-15 UTC. Claim boundary: qualitative implementation/guideline-context evidence only; not an efficacy trial, not a broad safety finding, and not evidence of approval/access outside the Australian authorized-prescribing context described by the article.
May 12, 2026 Last checked 2026-05-16 UTC Trial Update Company
Claim boundary.company-reported pipeline/capitalization and Phase 3-design tracker only; not approval, label, reimbursement, access, independent efficacy/safety confirmation, or proof that planned Phase 3 studies will start/succeed. Keep BPL-003, VLS-01, and EMP-01 separate from unrelated CNPV/company-primary-pending items.
AtaiBeckley company release says BPL-003 Phase 3 ReConnection remains on track for Q2 2026, with ReConnection-1 ~350 and ReConnection-2 ~230, MADRS Week 4 primary, and 52-week OLE; VLS-01 Phase 2 Elumina topline is anticipated Q4 2026; EMP-01 oral R-MDMA Phase 2a in SAD showed company-described convergent improvements; cash/securities were $209.9M with runway into 2029.
Source/tracker note
Last checked 2026-05-16 UTC. Claim boundary: company-reported pipeline/capitalization and Phase 3-design tracker only; not approval, label, reimbursement, access, independent efficacy/safety confirmation, or proof that planned Phase 3 studies will start/succeed. Keep BPL-003, VLS-01, and EMP-01 separate from unrelated CNPV/company-primary-pending items.
Conditions touched
Anxiety Disorder, CancerHealthyHealthy volunteersHealthy VolunteersHealthy, MDMA ('Ecstasy')MDMA ('Ecstasy'), Social InteractionMetabolism, InteractionMood Disorder, Substance-Related Disorders, Amphetamine-Related DisordersPost Traumatic Stress DisorderPTSD